一种基于益生菌的新型口服疫苗,用于对抗SARS-CoV-2Omicron变种B.1.1.52929的病毒
Eddie Chung Ting Chau1, Tsz Ching Kwong1, Chun Keung Pang1
1School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China.
International journal of molecular sciences
|September 28, 2023
概括
一种新的口服益生菌疫苗OMGVac有效地诱导了对子SARS-CoV-2Omicron变异的免疫反应. 这种安全和低成本的方法为未来的传染病疫苗开发提供了有希望的替代方案.
科学领域:
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 持续的COVID-19大流行需要可访问和有效的疫苗接种策略,特别是随着新的SARS-CoV-2变种的出现.
- 疫苗制造和分发的局限性凸显了需要替代的,低成本的输送方法.
- 转基因益生菌正在成为疫苗的有希望的口服输送工具.
研究的目的:
- 开发和评估一种口服益生菌疫苗,使用*Lactobacillus casei*进行工程设计,以表达SARS-CoV-2 Omicron变种 (B.1.1.529) 的抗原.
- 在临床前模型中评估这一新型疫苗 (OMGVac) 的安全性和免疫性.
主要方法:
- 经过工程 *Lactobacillus casei* 来表达SARS-CoV-2 Omicron变异的尖端蛋白质表位.
- 将复合益生菌疫苗 (OMGVac) 口服给金色叙利亚仓鼠.
- 通过生理学和组织病理学检查评估了全身免疫反应 (IgG) 和评估了安全性.
主要成果:
- OMGVac成功地引起了强大的IgG系统免疫反应,准了Omicron变体的尖端蛋白.
- 在接种疫苗的仓鼠中没有观察到任何不良的生理或组织病理影响,这表明了有利的安全性.
- 证明了重组益生菌作为诱导系统免疫力的活体载体的潜力.
结论:
- 工程化益生菌 *Lactobacillus casei* (OMGVac) 是一种安全有效的口服疫苗候选剂,可对抗SARS-CoV-2 Omicron变种.
- 这项研究验证了活体重组益生菌的使用,作为下一代针对新出现的传染病疫苗开发的可行平台.
更多相关视频
08:07A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
2.6K
12:09Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
42.9K
相关概念视频
Probiotics
Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
Development of the Oral Microbiota
The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
The Oral Microbiota
The oral microbiome includes a complex ecosystem comprising over 700 microbial species, identified through genomic sequencing and culture-based analyses to date. This community includes a core microbiome, found universally among individuals, and a variable component influenced by environmental factors such as diet, lifestyle, and host genetics. Site-specific conditions, including oxygen gradients, pH levels, and nutrient availability, determine the spatial distribution of these microorganisms...
Bacterial Gastroenteritis
Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...
Vaccines
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
